Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies

Những quyển sách tương tự

• Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
  Bằng: Alten, Rieke, et al.
  Được phát hành: (2020)
• FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
  Bằng: Genovese, Mark C., et al.
  Được phát hành: (2019)
• Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
  Bằng: Puri, Adeep, et al.
  Được phát hành: (2017)
• Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
  Bằng: Schreiber, Stefan, et al.
  Được phát hành: (2020)
• Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
  Bằng: Burmester, Gerd R, et al.
  Được phát hành: (2019)